Prescription Abandonment: Why It Happens and How to Reduce It

Prescription abandonment is what happens when a clinically justified decision has been made and the medicine never reaches the patient. It happens for two separate reasons that are routinely treated as one, which are cost arriving as a surprise and responsibility nobody holds. Reducing it is operating work rather than persuasion work. Almost nobody measures it as a commercial number.

Organizations measure the decisions they make and rarely measure what became of them. A prescription written is an event a commercial system can see, count and reward. A prescription never filled is an absence, and absences do not appear on dashboards built to count events. That accounting choice is why the largest and least contested loss in this industry is also the quietest.

The loss divides into two kinds, and the division carries the whole of the operating answer. Primary non-adherence is a prescription that is never filled at all. Early discontinuation is a prescription filled once or twice and then stopped. They have different causes, different owners and different remedies.

A qualification belongs at the front rather than buried in a footnote near the end. Some abandonment reflects sound clinical judgment or an informed patient choice, and those decisions deserve respect. The work is to separate them from the cases where somebody could not move forward because cost was unclear, information was missing or responsibility was unresolved.

The two kinds, and why the difference decides the work

Primary non-adherence happens in a window of days and usually at a price. A patient reaches a counter, hears a number she did not expect, and decides in seconds on incomplete information. The owner of that failure, where anyone owns it, sits in access and channel design rather than in patient support.

Early discontinuation happens in a window of weeks and usually at a question nobody answered. Side effects often arrive before any benefit does, a refill process has to work for the first time, and a pharmacy relationship has to be managed by somebody who has never managed one. The owner there sits in patient services, and the remedy is support that assumes inexperience rather than competence.

A program that treats the two as one thing will work on the wrong one, which is the pattern I meet most often. Copay support aimed at a patient who stopped because her injection technique was wrong solves nothing. Onboarding material sent to a patient who walked away from a price she could not afford arrives too late to matter. Both interventions are competent, and both are pointed at the wrong failure.

Separating a considered choice from a breakdown

What separates the two groups is whether the patient had what she needed in order to decide. A patient who declines a therapy after a frank conversation about cost and benefit has been well served. A patient who declines because she never learned that a lower cost route existed has not been. The two are indistinguishable in a dispense record, which is part of why this problem resists measurement.

Saying that plainly changes how the work gets framed internally. A program built without the distinction becomes a program to keep people on medicine, which is neither defensible nor particularly effective. A program built on the distinction has a narrower target and a much stronger claim, because it serves the patient who wanted to proceed and could not find out how.

Making the separation requires knowing why a particular patient stopped, reasonably close to when she stopped. Claims data reports the outcome and withholds the reason, which is why generic outreach tends to perform poorly against this problem. The reason usually exists somewhere in the system already, held by a pharmacist, a nurse or a field colleague who heard it directly.

What the evidence shows about cost at the counter

Cost is the clearest single predictor of a prescription never being collected. IQVIA data reported by Managed Healthcare Executive found that of prescriptions with a final cost above 250 dollars, 61 percent are not picked up by patients. That describes a therapy prescribed, approved and dispensed, which then failed to begin. Every expensive step in the commercial system had already succeeded.

The decision at that counter is made in seconds and on partial information. Patients rarely have any way of knowing at that moment whether assistance exists, whether a different channel costs less, or whether the number on the screen is final. The design gap sits in what she was handed to decide with rather than in the decision she made.

The other large driver is the mechanism examined on the companion page about prior authorization burden. A 2024 AMA physician survey found 82 percent of physicians reported that prior authorization at least sometimes leads to patients abandoning treatment. Physicians are reporting on a process they operate daily, which makes that a description of effect rather than a complaint about intent.

Why a written prescription is only intent

The reframing that makes abandonment commercial rather than charitable is short to state. Scientific value is realized when the patient accesses, starts, continues and benefits, not when the script is written. Written prescriptions are intent rather than realized value. A commercial system that counts scripts is counting its own intent and calling it performance.

That has consequences for how a brand team should read its own numbers. A strong prescription trend can coexist with a weak treated population, and the distance between them stays invisible in a scorecard built on the first figure. Growth reported in intent is eventually contradicted by revenue reported in reality.

Where one path hands off to the next

Abandonment is the Path to Fulfill failing into the Path to Adhere. The first runs from a clinical decision to a medicine in a patient's hand. The second runs from a first dose to the duration the trial actually demonstrated. Primary non-adherence belongs to the first and early discontinuation to the second, which is why one abandonment program usually sits properly in neither.

The handoff itself is where ownership disappears. A hub closes its case at a first fill, which is its defined success. A field team records a prescription written, which is its defined success. A patient who stops at week three has left both definitions behind while remaining inside the period her therapy was tested across.

What reduces a prescription never filled

Three pieces of operating work reduce primary non-adherence, and none of them is a message. The first is price transparency before the patient reaches the counter rather than after. A patient who learns her real cost in the exam room can discuss alternatives with a physician who is still in the room. A patient who learns it at a pharmacy learns it alone, standing up, with a queue behind her.

The second is benefit verification that happens before a patient is asked to act. Verification run after she has been told to collect a prescription converts a clinical decision into a personal errand with an unknown outcome. Running it first means she is only ever asked to do something that will actually work.

The third is a single named owner for a stalled case. Most access processes handle the standard path adequately and stall on the exception, which is where the clinically urgent cases concentrate. An exception with nowhere to go often becomes an abandonment by default, and nobody involved will ever learn that it did.

What reduces a prescription stopped early

Early discontinuation responds to onboarding that assumes a person has never done this before. Most onboarding I review reads as though the patient already has experience of specialty therapy, benefit renewals and injection devices. Writing it for a first time is accuracy about who is actually reading it rather than a courtesy.

The second piece is a working answer in the first three weeks, which is when side effects often arrive before any benefit does. A patient who can reach a person inside that window often continues. A patient who leaves a message and waits two days has already begun deciding.

The third is attention at the points where the process changes rather than at even intervals. A first refill, a ninety day renewal and an annual benefit reset are three moments when an administrative step may end a therapy that was working. Consumer-Grade is the standard a patient applies at each of them, because every other service in her life manages its own transitions without asking her to.

Why enrollment reporting hides the problem

The standard failure of hub reporting is measuring enrollment rather than progression. A hub that reports patients enrolled is reporting its own activity rather than the patient's progress. Enrollment counts can be made to rise in a period when fills are falling.

Progression measurement asks a different question at each stage. It asks how many prescriptions were written, how many were filled, how many started therapy, how many reached ninety days and how many persisted. Those stages make abandonment visible as a gap between two numbers rather than as an anecdote. The Realization Rate sits above that ladder as realized value divided by earned value.

How the loss compounds across the system

The scale becomes visible only when the stages are stacked on each other. An illustrative compounded scenario I published with TheyDo traces a billion dollars of earned value becoming roughly seven hundred million after prescriptions never filled. It falls again after early discontinuation, and settles close to four hundred and fifty million realized after long term adherence erosion. Those figures illustrate a shape rather than setting a benchmark.

The feature of that decline which should trouble a commercial leader most is that no competitor takes the difference. A prescription abandoned at a counter does not become a rival's prescription. It becomes nothing at all, which is why value leakage behaves unlike competitive loss and asks for a different kind of attention.

Competitive loss gets a war room, a counter detail and a pricing response. Leakage of this kind gets a line in a patient services update and no owner above it. That asymmetry reflects what the measurement system makes visible rather than anybody's priorities.

Key Takeaways

Prescription abandonment is a clinically justified decision that never reached the patient, and almost nobody measures it as a commercial number.
Primary non-adherence and early discontinuation have different causes, owners and remedies, so a program treating them as one will work on the wrong one.
Some abandonment reflects sound clinical judgment or informed patient choice, and the work is to separate those decisions from unresolved ones.
Cost arriving as a surprise at the counter is the clearest single predictor of a prescription never being collected.
Price transparency, benefit verification before the patient is asked to act, a named owner for stalled cases and onboarding written for a first time are the operating remedies.
A hub that reports patients enrolled is reporting its own activity rather than the patient's progress.

Diagnostic Questions to Consider

State what proportion of prescriptions written for your largest brand last quarter resulted in a dispense within thirty days.
Separate your abandonment into prescriptions never filled and prescriptions stopped early, then name the owner of each.
Describe how a patient learns her actual out of pocket cost, and at which point in the process she learns it.
Name the person a stalled case reaches today, and state how long reaching that person takes.
List what your patient services reporting would still show if enrollment counts were removed from it.

Closing Reflection

Abandonment has been discussed in this industry for a long time, mostly as a patient support concern and occasionally as a moral one. Neither framing ever earned it a budget line that survived a difficult quarter. Treated as the largest uncontested loss in the commercial system, it competes for funding on the same terms as everything else does.

The qualification set out at the top of this page holds throughout. Some patients decide against a therapy for reasons that are entirely sound, and no commercial system should be built to talk anybody out of a considered decision. The target is narrower and far more defensible, which is the patient who wanted to proceed and could not find out how.

What this asks for is a company willing to count what happened to its prescriptions rather than how many it wrote. That is a measurement change before it becomes an operating change, and the measurement change is the harder of the two. Everything useful follows from being able to see the gap at all.

About the Author

Wayne Simmons is the founder of The Customer Excellence AGENCY and the author of The Customer Excellence Enterprise (Wiley, 2024). He is founding faculty of the MS in Customer Experience Management at Michigan State University's Broad College of Business. He led global customer excellence in Pfizer's first Chief Marketing Organization and in Bayer's Customer Powerhouse.

The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.

< Older Post

Newer Post >

[PRACTICE NOTE] Your Call Plan Isn’t the Problem. Your Customer Context Is.

March 15, 2026

Why healthcare professionals now judge pharmaceutical engagement against the best experiences in their lives, and what that means for the future of commercial leadership. When commercial performance falters, the reflex inside many pharmaceutical organizations is to adjust the machinery of field execution. Leaders revisit call plans, recalibrate targeting models, and increase the volume of activity in the hope that more precision or more frequency will restore momentum. For decades this system has been treated as the central instrument of commercial performance, determining which physicians are prioritized, how frequently representatives engage, and how resources are deployed across territories. Yet the growing gap between commercial effort and commercial impact suggests a deeper issue. T he problem is rarely the design of the call plan itself. It is the context in which healthcare professionals now operate. Physicians are navigating increasingly complex clinical, administrative, and informational environments, and that evolving reality now shapes prescribing behavior far more than the cadence of promotional interactions. What many organizations are experiencing is a widening Customer Context Gap. Commercial systems were designed for a time when prescribing decisions could be influenced primarily through promotional interaction and product information. Today physicians operate inside a far more complex reality shaped by administrative burden, reimbursement constraints, digital information overload, and growing expectations for seamless support across the entire care journey. In this environment the physician’s decision is influenced not only by clinical evidence but also by how easily a therapy fits into the practical realities of care delivery. When commercial models remain anchored in promotional activity while the customer’s context has fundamentally changed, even the most disciplined call plan struggles to deliver the outcomes it was designed to produce. Closing this gap requires a different way of thinking about commercial performance. The question is no longer how to optimize promotional activity but how to align the organization around the real journeys through which physicians help patients receive therapy. Prescribing decisions unfold within complex sequences of clinical evaluation, reimbursement navigation, patient readiness, and ongoing support. When commercial strategy is designed around these journeys rather than isolated interactions, the role of the field force begins to evolve. Representatives are no longer positioned primarily as messengers of information but as partners in removing barriers that slow care. Organizations that recognize this shift begin redesigning their commercial systems accordingly, aligning field engagement, digital support, access programs, and patient services around the same goal: helping healthcare professionals help patients move from clinical intent to successful treatment. From Promotional Activity to Customer Journeys The pharmaceutical industry has historically organized commercial activity around the moment of promotion. Call plans, targeting models, and message sequencing were designed to influence prescribing behavior primarily through informational engagement with healthcare professionals. While this model brought structure and scale to commercial operations, it reflects an earlier era in which the path from clinical awareness to prescribing action was comparatively linear. Today the journey is far more complex. Physicians must navigate an intricate landscape of clinical evidence, treatment guidelines, payer requirements, prior authorization processes, patient affordability concerns, and adherence challenges. Prescribing a therapy is no longer a single decision point. It is the beginning of a chain of events that determines whether a patient ultimately receives and remains on treatment. This is why the commercial conversation must expand beyond the traditional moment of prescription to encompass three interconnected journeys. The first is the Path-to-Prescribe , where scientific evidence, clinical education, and confidence in the therapy shape the physician’s willingness to recommend treatment. The second is the Path-to-Fulfill, where access, affordability, patient readiness, and operational support determine whether that recommendation ultimately becomes therapy in the patient’s hands. The third is the Path-to-Adhere , where ongoing patient support, monitoring, and engagement determine whether patients remain on therapy long enough to realize the intended clinical benefit. Science drives the Path to Prescribe, where evidence, clinical education, and confidence in the therapy shape the physician’s willingness to recommend treatment. Experience shapes the Path to Fulfill, where access, affordability, and patient readiness determine whether that recommendation becomes therapy in the patient’s hands. Sustained outcomes depend on the Path to Adhere, where ongoing support, monitoring, and engagement ensure patients remain on therapy long enough to realize its intended clinical benefit. When commercial organizations focus almost exclusively on the first while leaving the latter journeys fragmented and burdened, a significant portion of therapeutic value is lost between intention and impact. In many therapeutic areas, the result appears in the persistent gap between prescriptions written, prescriptions filled, and therapies sustained—gaps that reflect not a failure of science but a failure of system design. Recognizing these three journeys shifts the unit of focus from promotional activity to the real-world pathways through which care is delivered. It reframes the role of the field force, the purpose of digital engagement, and the design of patient support programs around a single objective: reducing the friction that stands between clinical intent, treatment initiation, and sustained patient outcomes. Customer Context Is the New Commercial Variable For much of the pharmaceutical industry’s history, commercial performance was largely explained by a familiar set of variables. Product efficacy, clinical differentiation, promotional reach, and sales force execution determined the trajectory of most brands. When performance lagged, leaders adjusted those levers by refining segmentation, optimizing targeting, and recalibrating call plans. Today those traditional levers still matter, but they no longer explain commercial outcomes on their own. A far more powerful variable has entered the equation: customer context. HCPs now operate within an environment defined not only by clinical complexity and administrative burden but also by rising expectations shaped by their experiences outside healthcare. Physicians are also consumers. In their personal lives they interact daily with companies such as Apple, Amazon, Tesla, and Netflix that anticipate their needs, remove friction, and simplify complex processes through thoughtful design. These experiences quietly reset the benchmark for competence, responsiveness, and respect for their time. When those same physicians step into their clinical roles, they do not shed those expectations. They carry them with them. The contrast between the seamless orchestration of their consumer experiences and the fragmented systems surrounding many healthcare interactions becomes difficult to ignore. What once felt acceptable now feels unnecessarily burdensome. This dynamic represents the Consumer-Grade Imperative. Healthcare professionals increasingly evaluate pharmaceutical engagement not against other pharmaceutical companies but against the best experiences they encounter anywhere in their lives. In this environment even a clinically superior therapy can struggle if the surrounding system makes it difficult to initiate treatment, navigate reimbursement, or support patient adherence. Customer context therefore becomes the new commercial variable. It determines whether scientific differentiation translates into practical adoption. It shapes whether prescribing intent becomes therapy initiation and whether therapy initiation becomes sustained patient outcomes. Call plans were designed to manage activity. Customer context requires organizations to manage journeys. The Field Force in the Era of Customer Context Recognizing customer context as the defining commercial variable inevitably reshapes how the role of the field force is understood. For decades the pharmaceutical sales representative has been positioned primarily as the carrier of scientific information. Call plans optimized the frequency and sequencing of these interactions to ensure that physicians received consistent messaging. That role does not disappear, but the environment surrounding it has changed profoundly. Physicians today are navigating administrative burden, payer complexity, digital information overload, and increasing time pressure. In this environment they are not simply seeking more information. They are seeking clarity, simplicity, and support that helps them navigate the complexity surrounding treatment decisions. This shift transforms the representative from a messenger of information into something far more valuable: a partner in removing friction from the care journey. Conversations move beyond repeating clinical claims toward understanding the practical barriers that physicians and their teams face as they attempt to initiate and sustain therapy for patients. The most effective field forces are therefore supported by commercial systems designed around journeys rather than activities. Representatives are equipped not only with scientific messaging but with the insight and coordination required to address obstacles across prescribing, reimbursement, and patient support. Field engagement becomes a catalyst for problem solving rather than simply a vehicle for promotion. From Call Plans to Customer-Aligned Commercial Systems If customer context has become the defining commercial variable, then the systems designed to support the field must evolve accordingly. The traditional call plan was built to manage activity. It provided structure for how frequently physicians were engaged, how territories were covered, and how resources were deployed. Yet activity alone does not determine whether therapies ultimately reach patients. What determines impact is whether the commercial system surrounding the physician reduces or increases the burden of delivering care. A customer-aligned commercial system begins with the journeys through which physicians help patients move from diagnosis to treatment and beyond. Marketing clarifies the scientific story. Sales provides trusted relationships and real-time understanding of physician needs. Access teams simplify reimbursement pathways. Patient support programs reduce administrative burden. Digital engagement reinforces and extends human interaction. The result is a commercial system that operates less like disconnected functions and more like an integrated network designed to help physicians help patients. This is the essence of Customer Excellence. It aligns the entire commercial enterprise around the real-world context in which care is delivered. The problem was never the call plan. The problem was the context. Key Takeaways Commercial performance in pharma organizations has traditionally been managed through field execution mechanics, yet the effectiveness of those mechanics increasingly depends on how well they reflect the real-world context in which physicians operate. Customer context has become the most pivotal commercial variable as administrative burden, payer complexity, and consumer-grade expectations reshape how prescribing decisions are made. HCPs now evaluate pharmaceutical engagement against the best experiences they encounter anywhere in their lives, raising the standard for clarity, responsiveness, and ease. Optimizing promotional activity alone is no longer sufficient. Commercial success depends on reducing friction across the journeys physicians navigate as they move patients from diagnosis to treatment. Customer Excellence represents the structural response, aligning marketing, sales, access, digital engagement, and patient support around the real journeys of care delivery . Diagnostic Questions to Consider Are we optimizing the activity of our field force, or designing commercial systems that support the real journeys physicians navigate to help patients receive therapy? How well do we understand the administrative, reimbursement, and operational barriers physicians encounter after they decide to prescribe a therapy? Do our commercial systems reduce the burden placed on physicians and their staff , or unintentionally add to the complexity of care delivery? Are we benchmarking our engagement against other pharma companies , or against the best experiences physicians encounter in their lives as consumers? Have our investments in digital platforms simplified the physician’s experience, or multiplied the number of disconnected interactions they must manage? Are we still managing performance through activity metrics alone , or beginning to understand the context that ultimately determines whether therapies reach patients? Closing Reflection The pharma and life sciences industry has spent decades refining the mechanics of field execution. Call plans, segmentation models, and targeting systems brought structure and discipline to commercial organizations. Yet the environment surrounding physicians has evolved far more rapidly than the systems built to support them. Healthcare professionals now operate in a world defined by consumer-grade expectations for clarity, responsiveness, and ease. When the experience of engaging with a pharmaceutical company fails to reflect those expectations, the contrast becomes impossible to ignore. Organizations that recognize this shift will redesign their commercial systems around the realities of modern care delivery. They will move beyond managing activity and toward understanding the context in which physicians help patients receive treatment. In doing so they will close the gap between scientific innovation and real-world impact. Your breakthrough science deserves experiences worthy of it. Together, we turn customer excellence into real-world impact. About the Author Wayne Simmons is a hands-on commercial excellence architect and founder of The Customer Excellence Agency, where he partners with pharmaceutical and life sciences leaders to turn customer-centric ambition into durable commercial advantage. He previously served as Global Customer Excellence Lead within Pfizer’s Chief Marketing Organization and has held leadership roles with Bayer Pharmaceuticals and The Ritz-Carlton Leadership Center. Wayne writes The Customer-Centric Marketer newsletter and is the author of The Customer Excellence Enterprise: A Playbook for Creating Customers for Life. The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.

Tan building with a hanging sign against a clear blue sky